Sugi Predict

Sugi Predict / Compounds / SCHEMBL2111664

SCHEMBL2111664

SCHEMBL2111664

O=C(O)CCCCCN1C(=O)C=CC1=O.O=C1CCC(=O)N1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 7/20 0.76
▸ PTGS2 P35354 7/20 0.76
▸ MGLL Q99685 6/20 0.52
▸ FAAH O00519 4/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HSP90AA1 P07900 1/20 0.52
▸ TLR9 Q9NR96 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ XBP1 P17861 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ GPR35 Q9HC97 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4952666 0.94 PTGS1 (0.65) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL1069132 0.87 PTGS1 (0.54) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL43882 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL43969 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL8779419 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL24939859 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL3291535 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL7785894 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL6934781 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2
SCHEMBL8779453 0.87 PTGS1 (1.00) PTGS1PTGS2MGLLFAAHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113784728-B Bispecific T cell conjugates with cleavable cytokines for targeted immunotherapy 深圳康源久远生物技术有限公司 2024-08-13 — — CN disclosed
US-20240115655-A1 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS SIXTH STREET LENDING PARTNERS 2024-04-11 — — US disclosed
EP-4349363-A2 DOSING REGIMENS Apellis Pharmaceuticals, Inc. (US) 2024-04-10 — — EP disclosed
US-20240076317-A1 CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF SIXTH STREET LENDING PARTNERS 2024-03-07 — — US disclosed
CN-117580593-A Anthracycline antibody conjugates 思进公司 2024-02-20 — — CN disclosed
US-11903994-B2 Dosing regimens APELLIS PHARMACEUTICALS, INC. (US) 2024-02-20 — — US disclosed
US-11896705-B2 Functionalized polypeptides useful in hair treatment UAB FERENTIS (LT) 2024-02-13 — — US disclosed
CN-117337196-A Pegylated antibody hydroxyl-containing drug conjugates 深圳康源久远生物技术有限公司 2024-01-02 — — CN disclosed
EP-3359555-B1 DOSING REGIMENS APELLIS PHARMACEUTICALS INC (US) 2023-12-20 — — EP disclosed
US-11844841-B2 Dosing regimens and related compositions and methods APELLIS PHARMACEUTICALS, INC. (US) 2023-12-19 — — US disclosed
CN-101048659-A Monoclonal antibodies against progastrin APHTON CORP (US) 2007-10-03 — — CN disclosed
CN-1997669-A Monoclonal antibodies to gastrin hormone RECEPTOR BIOLOGIX INC (US) 2007-07-11 — — CN disclosed
EP-1794586-A1 MONOCLONAL ANTIBODIES TO PROGASTRIN APHTON CORPORATION (US) 2007-06-13 — — EP disclosed
US-20070066809-A1 Monoclonal antibodies to gastrin hormone CANCER ADVANCES, INC. 2007-03-22 — — US disclosed
EP-1730193-A2 MONOCLONAL ANTIBODIES TO GASTRIN HORMONE Receptor Biologix, Inc. (US) 2006-12-13 — — EP disclosed
WO-2006032980-A1 MONOCLONAL ANTIBOLIES TO PROGASTRIN RECEPTOR BIOLOGIX, INC. (US) 2006-03-30 — — WO disclosed
US-20060020119-A1 Monoclonal antibodies to gastrin hormone CANCER ADVANCES, INC. 2006-01-26 — — US disclosed
WO-2005095459-A2 MONOCLONAL ANTIBODIES TO GASTRIN HORMONE RECEPTOR BIOLOGIX, INC. (US) 2005-10-13 — — WO disclosed
US-20020044937-A1 PROTEIN-POLYCATION CONJUGATES BIRNSTIEL MAX L (AT) 2002-04-18 — — US disclosed
US-5922859-A INCLUDES NUCLEIC ACID TO BE TRANSFERED, INTERNALIZING FACTOR, BONDING FACTOR CONJUGATE, NON-COVALENTLY BOUND SUBSTANCES; FOR GENE THERAPY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 1999-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11896705-B2 Functionalized polypeptides useful in hair treatment PSAP, PLOD3, LNPEP PTGS1 4129/4885PTGS2 4170/4885MGLL 2807/4885
US-11844841-B2 Dosing regimens and related compositions and methods C1QBP, C3AR1, C9 PTGS1 2432/4885PTGS2 3607/4885MGLL 3477/4885
US-11903994-B2 Dosing regimens C3AR1, C1QBP, C9 PTGS1 2126/4885PTGS2 3230/4885MGLL 3569/4885
US-20240076317-A1 CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF C3AR1, C5AR1, SERPINC1 PTGS1 1785/4885PTGS2 2626/4885MGLL 4003/4885
US-20240115655-A1 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS C1QBP, C3AR1, C9 PTGS1 2432/4885PTGS2 3607/4885MGLL 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.